With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.101691-65-0,(Tetrahydro-2H-pyran-4-yl)methyl 4-methylbenzenesulfonate,as a common compound, the synthetic route is as follows.
To DMF (1.5 ml) was added NaH (60% in mineral oil, 46.1 mg, 1.152 mmol) and then 5-bromo-2-fluoropyridin-3 -amine (200 mg, 1.047 mmol). The reaction mixture was stirred at room temperature for 15 minutes. Then (tetrahy dro-2H-pyran-4-yl)methyl 4- methylbenzenesulfonate (283 mg, 1.047 mmol) was added and stirred at 40 C for 40 hours. The reaction was cooled to room temperature and 100 ml of ethyl acetate was added. The resulting mixture was washed with saturated sodium bicarbonate (2x), water (2x), brine, dried sodium sulfate, filtered and concentrated to dryness. The residue was purified by silica gel chromatography (40g column eluting with 0-40% ethyl acetate in heptane). The desired fractions were concentrated to yield 104 mg of the title compound as free base. LCMS (m/z): 288.9/290.9 (MH+), retention time = 0.88 min., 101691-65-0
Big data shows that 101691-65-0 is playing an increasingly important role.
Reference£º
Patent; NOVARTIS AG; ANTONIOS-MCCREA, William, R.; BARSANTI, Paul, A.; HU, Cheng; JIN, Xianming; MARTIN, Eric, J.; PAN, Yue; PFISTER, Keith, B.; SENDZIK, Martin; SUTTON, James; WAN, Lifeng; WO2012/66070; (2012); A1;,
Tetrahydropyran – Wikipedia
Tetrahydropyran – an overview | ScienceDirect Topics